PL3842436T3 - Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii - Google Patents

Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii

Info

Publication number
PL3842436T3
PL3842436T3 PL20216929.8T PL20216929T PL3842436T3 PL 3842436 T3 PL3842436 T3 PL 3842436T3 PL 20216929 T PL20216929 T PL 20216929T PL 3842436 T3 PL3842436 T3 PL 3842436T3
Authority
PL
Poland
Prior art keywords
imidazopyrimidine
schizophrenia
treatment
pharmaceutical compositions
imidazotriazine
Prior art date
Application number
PL20216929.8T
Other languages
English (en)
Inventor
Chun Eung Park
Young Koo JANG
Yong Je Shin
Ji Yeon Kim
Seung Mo HAM
Yong Gil Kim
Hye Kyung Min
Soo Bong CHA
Hyo Jun Jung
Ju Young Lee
Seung Nam Han
Jin Yong Chung
Eun Ju Choi
Chan Mi Joung
Jong Sil Park
Ji Won Lee
Nahm Ryune Cho
Eun Ju Ryu
Cheol Young Maeng
Original Assignee
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co., Ltd. filed Critical Sk Biopharmaceuticals Co., Ltd.
Publication of PL3842436T3 publication Critical patent/PL3842436T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20216929.8T 2015-02-26 2016-02-25 Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii PL3842436T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150027395 2015-02-26

Publications (1)

Publication Number Publication Date
PL3842436T3 true PL3842436T3 (pl) 2024-03-04

Family

ID=56788906

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20216929.8T PL3842436T3 (pl) 2015-02-26 2016-02-25 Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii
PL16755910T PL3262047T3 (pl) 2015-02-26 2016-02-25 Pochodne imidazopirymidyny i imidazotriazyny i kompozycje farmaceutyczne je zawierające

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16755910T PL3262047T3 (pl) 2015-02-26 2016-02-25 Pochodne imidazopirymidyny i imidazotriazyny i kompozycje farmaceutyczne je zawierające

Country Status (21)

Country Link
US (6) US9745310B2 (pl)
EP (2) EP3262047B1 (pl)
JP (1) JP6692367B2 (pl)
KR (1) KR102577178B1 (pl)
CN (1) CN107635994B (pl)
AR (1) AR103769A1 (pl)
AU (1) AU2016224227B2 (pl)
BR (1) BR112017018192B1 (pl)
CA (1) CA2976422C (pl)
CL (1) CL2017002163A1 (pl)
DK (2) DK3842436T3 (pl)
ES (2) ES2964324T3 (pl)
FI (1) FI3842436T3 (pl)
IL (1) IL254070B (pl)
MX (1) MX381323B (pl)
PL (2) PL3842436T3 (pl)
PT (2) PT3262047T (pl)
RU (1) RU2710556C2 (pl)
TW (1) TWI713497B (pl)
WO (1) WO2016137260A1 (pl)
ZA (1) ZA201705333B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713497B (zh) 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
CN114929230B (zh) * 2019-10-21 2024-11-29 爱思开生物制药株式会社 咪唑并嘧啶或咪唑并三嗪化合物用于预防、减轻或治疗认知障碍或者用于改善认知功能的用途
EP4049661A4 (en) * 2019-10-21 2023-11-08 SK Biopharmaceuticals Co., Ltd. USE OF AN IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUND TO PREVENT, RELIEF OR TREAT DEVELOPMENTAL DISABILITIES

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
US6596731B2 (en) * 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
EP1726585A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd DIARYLSUBSTITUTED FIVE-GLOSS HETEROCYCLUS DERIVAT
ES2340321T3 (es) * 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
KR101532256B1 (ko) * 2006-11-22 2015-06-29 인사이트 코포레이션 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
EP2162136A4 (en) 2007-06-03 2012-02-15 Univ Vanderbilt GLUTAMATE METABOTROPIC POSITIVE RECEPTOR-BASED ALLOSTERIC-MODULATOR BENZAMIDE DERIVATIVES (MGLUR5) AND METHODS OF MAKING AND USING THEM
EP2421370A4 (en) 2009-04-23 2012-12-12 Merck Sharp & Dohme 2-alkyl-piperidine-mGluR5 receptor MODULATORS
AR078172A1 (es) 2009-09-15 2011-10-19 Sanofi Aventis Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur
RU2012116124A (ru) 2009-09-21 2013-10-27 Вандербилт Юниверсити О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5
CA2784768C (en) * 2009-12-29 2015-02-03 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
US8785481B2 (en) * 2010-09-29 2014-07-22 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
US8703946B2 (en) * 2010-12-08 2014-04-22 Vanderbilt University Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors
JP2013545822A (ja) * 2010-12-17 2013-12-26 ヴァンダービルト ユニバーシティー mGluR5受容体のアロステリック調節剤としての、二環式トリアゾールラクタムおよびピラゾールラクタム
PE20140236A1 (es) * 2011-02-23 2014-03-14 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS
WO2012125732A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
ES2790358T3 (es) * 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular
US9422279B2 (en) * 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI713497B (zh) 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物

Also Published As

Publication number Publication date
KR20160104579A (ko) 2016-09-05
EP3262047B1 (en) 2021-01-06
EP3842436A1 (en) 2021-06-30
DK3262047T3 (da) 2021-03-01
KR102577178B1 (ko) 2023-09-11
BR112017018192B1 (pt) 2023-11-21
JP2018506561A (ja) 2018-03-08
EP3842436B1 (en) 2023-11-08
US20200277298A1 (en) 2020-09-03
FI3842436T3 (fi) 2024-01-24
CN107635994B (zh) 2019-11-05
US20170349597A1 (en) 2017-12-07
BR112017018192A2 (pt) 2018-04-17
PT3842436T (pt) 2023-12-28
CA2976422A1 (en) 2016-09-01
ES2854288T3 (es) 2021-09-21
ES2964324T3 (es) 2024-04-05
US20210300933A1 (en) 2021-09-30
ZA201705333B (en) 2019-07-31
US20190031669A1 (en) 2019-01-31
HK1244275A1 (zh) 2018-08-03
PL3262047T3 (pl) 2021-05-31
DK3842436T3 (da) 2024-02-05
AU2016224227A1 (en) 2017-08-31
AU2016224227B2 (en) 2020-01-16
MX381323B (es) 2025-03-12
PT3262047T (pt) 2021-02-25
IL254070B (en) 2020-07-30
TW201639848A (zh) 2016-11-16
US20240352023A1 (en) 2024-10-24
US9745310B2 (en) 2017-08-29
US20160251361A1 (en) 2016-09-01
US10100057B2 (en) 2018-10-16
EP3262047A4 (en) 2018-08-01
MX2017010630A (es) 2017-11-16
CA2976422C (en) 2023-09-26
AR103769A1 (es) 2017-05-31
EP3262047A1 (en) 2018-01-03
CL2017002163A1 (es) 2018-06-22
JP6692367B2 (ja) 2020-05-13
RU2017131514A3 (pl) 2019-05-31
RU2710556C2 (ru) 2019-12-27
TWI713497B (zh) 2020-12-21
IL254070A0 (en) 2017-10-31
US12037338B2 (en) 2024-07-16
US11046702B2 (en) 2021-06-29
WO2016137260A1 (en) 2016-09-01
RU2017131514A (ru) 2019-03-26
CN107635994A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
IL272820A (en) History of sulfamolepyrolamide and their use as hepatitis B drugs
IL276333B (en) Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
IL247239A0 (en) Complexes of sirolimus and its derivatives, a process for their preparation and pharmaceutical preparations containing them
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
PL3842436T3 (pl) Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii
EP3148570A4 (en) Pharmaceutical composition for preventing or treating skin rash
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
ZA201607353B (en) Bicyclic derivatives and pharmaceutical composition including the same
EP3322435A4 (en) Pharmaceutical compositions useful for the treatment of tissue injury
GB201513543D0 (en) Compositions for use in the treatment of diabetes
IL257689A (en) Pharmacological preparations and methods for the treatment of diseases associated with hypoxia
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HK40009824A (en) Pharmaceutical composition for use in the treatment of prostate pathologies
GB201714241D0 (en) Pharmaceutical compositions for the treatment of proteinopathies
EP3434271A4 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A GAUZE SYTHEM IN POIKILODERMIA
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases